Inhibrx Biosciences (INBX) Earnings Analysis
Inhibrx Biosciences (INBX) next reports earnings on 2026-08-12, consensus EPS -2.28 USD. Last quarter (2026-05-14) it beat with EPS -2.15 USD vs -2.37 USD est (+9.3%). It has beaten estimates in 3/7 recent quarters (43%). Trailing P/E -10.24.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does INBX next report earnings?
| Next earnings date | 2026-08-12 |
|---|---|
| Consensus EPS estimate | -2.28 USD |
| Revenue estimate | n/a |
INBX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-14 | -2.15 USD | -2.37 USD | +9.3% | Beat |
| 2026-03-19 | -2.11 USD | -2.08 USD | -1.4% | Miss |
| 2025-11-14 | -2.28 USD | -2.08 USD | -9.6% | Miss |
| 2025-08-13 | -1.85 USD | -2.92 USD | +36.6% | Beat |
| 2025-05-14 | -2.8 USD | -2.55 USD | -9.8% | Miss |
| 2025-03-17 | -3.09 USD | -2.88 USD | -7.3% | Miss |
| 2024-11-14 | -2.84 USD | -3.06 USD | +7.2% | Beat |
Beat rate: 3/7 (43%) over reported quarters with consensus data.
INBX valuation and analyst view
| Trailing P/E | -10.24 |
|---|---|
| Trailing EPS | -8.35322 USD |
| Price / book | -63.66 |
| Dividend yield | 0.00% |
| Market cap | 1.27B |
| Analyst consensus | Buy (3 buy / 2 hold / 0 sell) |
| Avg price target | 325 USD |
Related research pages
Frequently asked questions
When is Inhibrx Biosciences (INBX)'s next earnings date?
Inhibrx Biosciences is next scheduled to report on 2026-08-12, with a consensus EPS estimate of -2.28 USD.
Did INBX beat earnings last quarter?
In its 2026-05-14 report, INBX posted EPS of -2.15 USD versus a -2.37 USD estimate — a beat of 9.3%.
What is INBX's earnings track record?
Over the last 7 reported quarters with consensus data, INBX beat estimates 3 times (43%).
What is INBX's current P/E ratio and EPS?
INBX trades at a trailing P/E of -10.24 on trailing EPS of -8.353224254090472 USD.
What do analysts rate INBX?
Analyst consensus is "Buy" across 5 ratings (0 strong buy, 3 buy, 2 hold, 0 sell, 0 strong sell). Average 12-month price target: 325 USD.